• Press Release

Researchers Identify a Protein That Is Critical for Wound Healing after a Central Nervous System Injury

  • New York, NY
  • (March 02, 2020)

Plexin-B2, an axon guidance protein in the central nervous system (CNS), plays an important role in wound healing and neural repair following spinal cord injury (SCI), according to research conducted at the Icahn School of Medicine at Mount Sinai and published today in Nature Neuroscience. The study’s findings could aid the development of therapies that target axon guidance pathways for more effective treatment of SCI patients. 

Tissue repair after SCI requires the mobilization of immune and glial cells to form a protective barrier that seals the wound, facilitates debris clearing and contains inflammation. Building this barrier involves a process called corralling wherein microglia (immune cells in the CNS) and macrophages (immune cells that originate from blood) form a barrier around the lesion that separates healthy and necrotic tissue. In this study, researchers found that this corralling begins early in the healing process and requires Plexin-B2, a protein that facilitates the movement of immune cells by steering them away from colliding cells.

Researchers found that the deletion of Plexin-B2 in microglia and macrophages impaired corralling, which led to tissue damage, inflammatory spillover, and hindered the regeneration of axons (slender part of a nerve cell where impulses are conducted).

“The role of microglia and macrophages in the spatial organization of glial cells around the injury site via an axon guidance receptor is quite unexpected” said lead investigator Hongyan Jenny Zou, MD, PhD, Professor of Neurosurgery and Neuroscience at the Icahn School of Medicine at Mount Sinai.

Tissue repair in the CNS relies on a coordinated response from diverse cell types in overlapping phases. This complexity makes it difficult to distinguish specific roles of glial cell populations. Previously, astrocytes (supporting glial cells) were presumed to be the main driver for corralling. However, this study identified the critical contribution of injury-activated microglia/macrophages, as well as the role of Plexin-B2 in corralling. Understanding the signaling pathways and interactions of glial cells with each other and the injury environment is fundamental to improving neural repair after a traumatic brain or spinal cord injury.

This research was supported by grants from the National Institutes of Neurological Disorders and Stroke, the Craig H. Neilsen Foundation, the New York State Spinal Cord Injury Research Board, and the National Institute on Aging and the National Institute on Drug Abuse.


About the Mount Sinai Health System

Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.

As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.

Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.